ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,171.12
0.61%
Dow Jones
39,308.00
-0.06%
Gold vs US Dollar
2,359.625
1.26%
Brent Oil
86.945
0.04%
Bitcoin
60,187.12
0.04%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX

  6. Medicenna Therapeutics Corp (MDNA) Share Price

MDNA Medicenna Therapeutics Corp

1.81
-0.10 (-5.24%)
03 Jul 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Medicenna Therapeutics Corp TSX:MDNA Toronto Stock Exchange Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.10 -5.24 1.81 1.77 1.92 1.89 1.77 1.89 76,566 20:10:10   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics  -25.47M -0.3657 -4.95 126.04M
 Type  Size  Price  Time  Units 
  200 1.81 19:58:56 CAD
 
Recent News
DateTimeSource
HeadlineMore MDNA News
27/06/202413:18GLOBEMedicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
26/06/202412:47GLOBEMedicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe
03/06/202413:00GLOBEMedicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
31/05/202414:29GLOBEMedicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
22/05/202412:00GLOBEMedicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
13/05/202412:00GLOBEMedicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
30/04/202416:07GLOBEMedicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Period
Draw mode
Data Downloads for MDNA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Medicenna Therapeutics Corp Articles